Global Parkinson’s Disease Drugs Market to Reach Approximate Value of US$ 5 Billion by 2022

Noida, Uttar Pradesh, September 6, 2017 /– Parkinson’s disease is a chronic and progressive disorder of the nervous system. This disease is caused by the lack of dopamine in the brain. According to Parkinson’s Foundation, more than 10 Million people are living with Parkinson’s disease worldwide. Out of these, nearly 1 Million affected people are found in America. Various drugs are used for controlling the symptoms of Parkinson’s disease.

According to our report, “Global Parkinson’s Disease Drugs Market Outlook 2022“, the Global Parkinson’s Disease Drugs Market is expected to grow at a CAGR of around 4% from 2016 – 2022. The market segmentations by type of therapy and by geography have been mentioned in the report. The global Parkinson’s disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine agonist therapy, MAO-B inhibitor therapy, COMT inhibitor therapy and other type of therapies. Amongst all the types of therapies, levodopa therapy is the potent for the treatment of Parkinson’s disease.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global market for Parkinson’s disease drugs. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson’s disease drugs industry. Pipeline of Parkinson’s disease drugs have also been mentioned in the report.

The report also covers the key players of the global Parkinson’s disease drugs market. For every player, a brief business overview and key financials has been provided. The product portfolio, product pipeline and recent developments of each player have also been listed down. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Parkinson’s disease drugs market.

Some of the key findings of the report are:

– Stem Cell Therapies – Revolutionizing Parkinson Treatment

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM914.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

Notes to Editor

About RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Related Press Releases: